The following discussion and analysis of our financial condition and results of
operations should be read in conjunction with the consolidated financial
statements and related notes, which are included in this Annual Report on Form
10-K.
Overview
We are a company focused on biohacking the aging code through nutrigenomics, the
study of how nutrition and naturally occurring compounds affect human genes to
support good health. We are dedicated to helping people achieve their health,
wellness and financial goals. We provide quality, scientifically-validated
products and a financially rewarding direct sales opportunity to customers and
independent distributors. We engage in the identification, research, development
and distribution of advanced nutrigenomic activators, dietary supplements,
nootropics, pre- and pro-biotics, weight management, and skin and hair care
products. We currently sell our products to customers and independent
distributors in two geographic regions that we have classified as the Americas
region and the Asia/Pacific & Europe region.
The success and growth of our business is primarily based on the effectiveness
of our independent distributors to attract and retain customers in order to sell
our products and our ability to attract and retain independent distributors.
When we are successful in attracting and retaining independent distributors and
customers, it is largely because of:
•Our products, including Protandim®, our line of scientifically-validated
dietary supplements, LifeVantage® Omega+ and ProBio dietary supplements,
TrueScience®, our line of skin and hair care products, Petandim® for Dogs, our
companion pet supplement formulated to combat oxidative stress in dogs, Axio®,
our nootropic energy drink mixes, and PhysIQ™, our smart weight management
system;
•Our compensation plan and other sales initiatives; and
•Our delivery of superior customer service.
As a result, it is vital to our success that we leverage our product development
resources to develop and introduce compelling and innovative products and
provide opportunities for our independent distributors to sell these products in
a variety of markets. We sell our products in the United States, Mexico, Japan,
Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands,
Germany, Taiwan, Austria, Spain, Ireland, Belgium and New Zealand. We also sell
our products in a number of countries to customers for personal consumption
only. In addition, we sell our products in China through our cross-border
e-commerce business model. Entering a new market requires a considerable amount
of time, resources and continued support. If we are unable to properly support
an existing or new market, our revenue growth may be negatively impacted.
Impact of COVID-19 on Our Business
The pandemic caused by an outbreak of a new strain of coronavirus ("COVID-19")
has resulted, and is likely to continue to result, in significant national and
global economic disruption and may adversely affect our business. Uncertainty
exists concerning the magnitude of the impact and duration of the COVID-19
pandemic. As of the date of this filing, we have experienced multiple
disruptions at the corporate level as we have transitioned our corporate
workforce to a remote working environment, closed some of our showrooms and will
call locations in international markets and cancelled multiple planned events in
order to comply with group meeting restrictions. Our independent distributors
have also experienced disruptions. Specifically, in Japan, independent
distributors are required to provide a hard-copy introductory packet
(gaiyoshomen) in person to each person they approach to sponsor as an
independent distributor before presenting our products and business opportunity.
This requirement inhibits distributors from connecting with potential new
distributors virtually or through social
                                       37
--------------------------------------------------------------------------------

media. Accordingly, quarantines, avoidance of public places and general concerns
about physical distancing related to COVID-19 or otherwise can significantly
reduce the ability for independent distributors to meet people in person and
commence the enrollment process. Elsewhere, our independent distributors have
begun to adapt their approach for customer outreach and enrollment, including
transitioning to a stronger social media presence, in an effort to sustain their
sales volume. Our business may, in the future, experience additional disruptions
and be negatively impacted by the COVID-19 pandemic, including as a result of
limitations on the ability of our suppliers to manufacture, or procure from
manufacturers, the products we sell or any of the raw materials or components
required in the production process, or to meet delivery requirements and
commitments; limitations on the ability of our employees to perform their work
due to illness caused by the pandemic or local, state, or federal orders
requiring employees to remain at home; limitations on the ability of carriers to
deliver our products to customers; limitations on the ability of our independent
distributors to conduct their businesses and purchase our products; and
limitations on the ability of our independent distributors or customers to
continue to purchase our products due to decreased disposable income.
We have made modifications, and are evaluating additional potential
modifications that may be needed, to protect our supply chain and preserve
adequate liquidity to ensure that our business can continue to operate during
this uncertain time. Some states have issued executive orders requiring all
workers to remain at home, unless their work is critical, essential, or
life-sustaining. We have transitioned all of our corporate employees to a work
from home model and, to date, our employees are performing well in the new
environment. With respect to liquidity, we are evaluating and taking actions to
ensure that we continue to responsibly manage expenses across our organization.
While we are unable to determine or predict the nature, duration or scope of the
overall impact that the COVID-19 pandemic will have on our business, results of
operations, liquidity or capital resources, we will continue to actively monitor
the situation and may take further actions that alter our business operations as
may be required by federal, state or local authorities or that we determine are
in the best interests of our employees, independent distributors, customers, and
stockholders.
Our Products
Our line of scientifically-validated dietary supplements includes Protandim®
NRF1 Synergizer®, Protandim® Nrf2 Synergizer®, Protandim® NAD Synergizer™,
LifeVantage® Omega+ and LifeVantage® ProBio. The Protandim® NRF1 Synergizer® is
formulated to increase cellular energy and performance by boosting mitochondria
production to improve cellular repair and slow cellular aging. The Protandim®
Nrf2 Synergizer® contains a proprietary blend of ingredients and has been shown
to combat oxidative stress and enhance energy production by increasing the
body's natural antioxidant protection at the genetic level, inducing the
production of naturally-occurring protective antioxidant enzymes including
superoxide dismutase, catalase, and glutathione synthase. The Protandim® NAD
Synergizer™ was specifically formulated to target cell signaling pathways
involved in the synthesis and recycling of a specific molecule called NAD
(nicotinamide adenine dinucleotide), and has been shown to double sirtuin
activity, supporting increased health, focus, energy, mental clarity and mood.
LifeVantage® Omega+ is a dietary supplement that combines DHA and EPA Omega-3
fatty acids, Omega-7 fatty acids, and Vitamin D3 to support cognitive health,
cardiovascular health, skin health, and the immune system. LifeVantage® ProBio
is a dietary supplement designed to support optimal digestion and immune system
function. Our TrueScience® line of anti-aging skin and hair care products
includes TrueScience® Facial Cleanser, TrueScience® Perfecting Lotion,
TrueScience® Eye Serum, TrueScience® Anti-Aging Cream, TrueScience® Hand Cream,
TrueScience® Invigorating Shampoo, TrueScience® Nourishing Conditioner and
TrueScience® Scalp Serum. Petandim® for Dogs is a supplement specially
formulated to combat oxidative stress in dogs through Nrf2 activation. Axio® is
our line of nootropic energy drink mixes formulated to promote alertness and
support mental performance. PhysIQ™ is our smart weight management system which
includes PhysIQ™ Fat Burn, PhysIQ™ Prebiotic and PhysIQ™ Whey Protein, all
formulated to aid in weight management. The following table shows revenues by
major product line for the fiscal years ended June 30, 2020, 2019 and 2018(1):
                                                                                     Years ended June 30,
                                                        2020                                                    2019                                       2018
Protandim® product line                    $ 156,335              67.1  %       $ 144,100              63.8  %       $ 130,094              64.0  %
TrueScience® product line                     23,739              10.2  %          24,853              11.0  %          20,881              10.3  %
Other                                         52,841              22.7  %          57,005              25.2  %          52,229              25.7  %
Total                                      $ 232,915             100.0  %       $ 225,958             100.0  %       $ 203,204             100.0  %


(1) Certain prior year numbers have been updated to reflect current year product
line classification.
Our revenue is largely attributed to two product lines, Protandim® and
TrueScience®, which each accounted for more than 10% of total revenue for each
of the fiscal years ended June 30, 2020 and 2018. For the fiscal year ended June
30, 2019, Protandim® was the only product line that accounted for more than 10%
of total revenue. On a combined basis, these products
                                       38
--------------------------------------------------------------------------------

represent approximately 77.3%, 74.8% and 74.3% of our total net revenue for the
fiscal years ended June 30, 2020, 2019 and 2018, respectively.
We currently have additional products in development. Any delays or difficulties
in introducing compelling products or attractive initiatives or tools into our
markets may have a negative impact on our revenue and our ability to attract new
independent distributors and customers.
Accounts
Because we primarily utilize a direct selling model for the distribution of a
majority of our products, the success and growth of our business depends in
large part on the effectiveness of our independent distributors to attract and
retain customers to sell our products to, and our ability to attract new and
retain existing independent distributors. Changes in our product sales are
typically the result of variations in product sales volume relating to
fluctuations in the number of active independent distributors and customers
purchasing our products. The number of active independent distributors and
customers is, therefore, used by management as a key non-financial measure.
The following tables summarize the changes in our active accounts by geographic
region. These numbers have been rounded to the nearest thousand as of the dates
indicated. For purposes of this report, we define "Active Accounts" as only
those independent distributors and customers who have purchased from us at any
time during the most recent three-month period, either for personal use or for
resale.
                                                           As of June 30,
                                                                                                                                                  Change
                                                                                                                                                   from
                                                                                                                                                  Prior
                                            2020                                                        2019                                       Year       Percent Change
Active Independent
Distributors
  Americas                            49,000             67.1  %          44,000                 66.7  %           5,000              11.4  %
  Asia/Pacific & Europe               24,000             32.9  %          22,000                 33.3  %           2,000               9.1  %
    Total Active Independent
Distributors                          73,000            100.0  %          66,000                100.0  %           7,000              10.6  %

Active Customers
  Americas                            83,000             78.3  %          95,000                 79.8  %         (12,000)            (12.6) %
  Asia/Pacific & Europe               23,000             21.7  %          24,000                 20.2  %          (1,000)             (4.2) %
    Total Active Customers           106,000            100.0  %         119,000                100.0  %         (13,000)            (10.9) %

Active Accounts
  Americas                           132,000             73.7  %         139,000                 75.1  %          (7,000)             (5.0) %
  Asia/Pacific & Europe               47,000             26.3  %          46,000                 24.9  %           1,000               2.2  %
    Total Active Accounts            179,000            100.0  %         185,000                100.0  %          (6,000)             (3.2) %


Income Statement Presentation
We report revenue in two geographic regions and we translate revenue from each
market's local currency into U.S. Dollars using weighted-average exchange rates.
Revenue consists primarily of product sales, fee revenue, and shipping and
handling fees, net of applicable sales discounts. Revenue is recognized at the
time of shipment, which is when the passage of title and risk of loss to
customers occurs. Also reflected in revenue is a provision for product returns
and allowances, which is estimated based on our historical experience. The
following table sets forth net revenue information by region for the years
indicated. The following table should be reviewed in connection with the tables
presented under "Results of Operations" (in thousands):
                                                 For the fiscal years ended June 30,
                                   2020                                          2019                                2018
Americas                $   166,336         71.4  %    $ 163,236         72.2  %    $ 151,609         74.6  %
Asia/Pacific & Europe        66,579         28.6  %       62,722         27.8  %       51,595         25.4  %
Total                   $   232,915        100.0  %    $ 225,958        100.0  %    $ 203,204        100.0  %


                                       39

--------------------------------------------------------------------------------

Cost of sales primarily consists of costs of products purchased from and
manufactured by third-party vendors, costs of adjustments to inventory carrying
value, and costs of marketing materials which we sell to our independent
distributor sales force, as well as freight, duties and taxes associated with
the import and export of our products. As our international revenue increases as
a percentage of total revenue, cost of sales as a percentage of revenue likely
will increase as a result of additional duties, freight, and other factors, such
as changes in currency exchange rates.
Commissions and incentives expenses are our most significant expenses and are
classified as operating expenses. Commissions and incentives expenses include
sales commissions paid to our independent distributors, special incentives and
costs for incentive trips and other rewards. Commissions and incentives expenses
do not include any amounts we pay to our independent distributors related to
their personal purchases. Commissions paid to independent distributors on
personal purchases are considered a sales discount and are reported as a
reduction to net revenue. Our global sales compensation plan, which we employ in
all our markets, is an important factor in our ability to attract and retain our
independent distributors. Under our global sales compensation plan, independent
distributors can earn commissions for product sales to their customers as well
as the product sales made through the sales networks they have developed and
trained. We do not pay commissions on marketing materials that are sold to our
independent distributors. Commissions and incentives expenses, as a percentage
of net revenue, may be impacted by the timing and magnitude of
non-commissionable revenue derived from the sales of marketing materials, event
tickets, and promotional items, investment in our Red Carpet program,
limited-time offers and the timing, magnitude and number of incentive trips and
other promotional activities. From time to time, we make modifications and
enhancements to our global sales compensation plan in an effort to help motivate
our sales force and develop leadership characteristics, which can have an impact
on commissions and incentives expenses.
Selling, general and administrative expenses include wages and benefits, stock
compensation expenses, marketing and event costs, professional fees, rents and
utilities, depreciation and amortization, research and development, travel costs
and other operating expenses. Wages and benefits and stock compensation expenses
represent the largest component of selling, general and administrative expenses.
Marketing and event costs include costs of distributor conventions and events
held in various markets worldwide, which we expense in the period in which they
are incurred. Marketing and event costs also include expenses associated with
our sponsorship of the Major League Soccer team, Real Salt Lake.
Sales to customers outside the United States are transacted in the respective
local currencies and are translated to U.S. Dollars at weighted-average currency
exchange rates for each monthly accounting period to which they relate.
Consequently, our net sales and earnings are affected by changes in currency
exchange rates. In general, sales and gross profit are affected positively by a
weakening U.S. Dollar and negatively by a strengthening U.S. Dollar. Currency
fluctuations, however, have the opposite effect on our commissions paid to
independent distributors and selling, and general and administrative expenses.
In our revenue discussions that follow, we approximate the impact of currency
fluctuations on revenue by translating current year revenue at the average
exchange rates in effect during the comparable prior year periods.
Results of Operations
For the fiscal years ended June 30, 2020, 2019 and 2018, we generated net
revenue of $232.9 million, $226.0 million and $203.2 million, respectively,
recognized operating profit of $15.5 million, $9.8 million and $10.3 million,
respectively, and recognized net income of $11.5 million, $7.4 million and $5.8
million, respectively.
                                       40
--------------------------------------------------------------------------------

The following table presents certain consolidated earnings data as a percentage of net revenue for the years indicated(1):

For the fiscal years ended June 30,


                                                                  2020                        2019                     2018
Revenue, net                                                            100.0  %                 100.0  %                 100.0  %
Cost of sales                                                            16.3                     16.8                     17.1

Gross profit                                                             83.7                     83.2                     82.9
Operating expenses:
Commissions and incentives                                               47.9                     48.1                     48.3
Selling, general and administrative                                      29.2                     30.8                     29.4

Total operating expenses                                                 77.1                     78.9                     77.7
Operating income                                                          6.6                      4.3                      5.2
Other expense:
Interest expense                                                         (0.1)                    (0.2)                    (0.2)
Other expense, net                                                       (0.3)                    (0.1)                    (0.2)

Total other expense                                                      (0.3)                    (0.3)                    (0.4)
Income before income taxes                                                6.3                      4.0                      4.8
Income tax expense                                                       (1.3)                    (0.8)                    (1.9)
Net income                                                                5.0  %                   3.2  %                   2.9  %

(1) Certain percentages may not add due to rounding.




Comparison of Fiscal Years Ended June 30, 2020 and 2019
Revenue, net. We generated net revenue of $232.9 million and $226.0 million
during the fiscal years ended June 30, 2020 and 2019, respectively. Foreign
currency fluctuations positively impacted our net revenue $0.4 million or 0.2%.
During fiscal 2020, Australia and New Zealand generated a strong year over year
revenue increase of 54.9%, due in part to the successful on the ground launch of
New Zealand in November 2019. Revenue in the United States, Japan, Canada and
Thailand grew steadily, while revenue declined on a year over year basis in our
Greater China region and Mexico. We launched our new Protandim® NAD Synergizer
in October 2019 and have seen encouraging initial sales. We rolled out a free
shipping program and pricing update, beginning in January 2020. All of these
activities helped contribute to increased average order sizes as compared to the
prior fiscal year.
Americas. The following table sets forth revenue for the fiscal years ended
June 30, 2020 and 2019 for the Americas region (in thousands):
                          For the fiscal years ended June 30,
                          2020                               2019         % change
United States     $        155,480                       $ 151,966           2.3  %
Other                       10,856                          11,270          (3.7) %
Americas Total    $        166,336                       $ 163,236           1.9  %


Revenue in the Americas region for the fiscal year ended June 30, 2020 increased
$3.1 million, or 1.9%, compared to the prior year. Revenue in the Americas
increased due to the continued investment in our red carpet program, the
introduction of our new Protandim® NAD Synergizer and the roll out of our free
shipping program and pricing updates in January 2020.
                                       41
--------------------------------------------------------------------------------

Asia/Pacific & Europe. The following table sets forth revenue for the fiscal
years ended June 30, 2020 and 2019 for the Asia/Pacific & Europe region and its
principal markets (in thousands):
                                      For the fiscal years ended June 30,
                                      2020                                2019         % change
Japan                         $         42,343                         $ 40,796           3.8  %
Australia & New Zealand                  9,065                            5,851          54.9  %
Greater China                            6,682                            7,924         (15.7) %
Other                                    8,489                            8,151           4.1  %
Asia/Pacific & Europe Total   $         66,579                         $ 62,722           6.1  %


Revenue in the region for the fiscal year ended June 30, 2020 was positively
impacted approximately $0.7 million, or 1.1%, by foreign currency exchange rate
fluctuations.
We saw encouraging revenue growth in Japan, which increased 3.8% year over year
on a U.S. Dollar basis and 1.1% on a constant currency basis. During the fiscal
year ended June 30, 2020, the Japanese yen, on average, strengthened against the
U.S. Dollar, positively impacting our revenue in this market by $1.1 million or
2.8%. Revenue in our Australia and New Zealand markets grew significantly during
fiscal 2020. We successfully completed our full on the ground launch of New
Zealand in November 2019. The launch of New Zealand created synergies between
our Australian and New Zealand distributor organizations and customer bases,
further driving the growth within the region. Active accounts in the region
increased slightly by 2.2% on a year over year basis also contributing to the
growth.
Revenue in our Greater China region decreased by 15.7% year over year as we
experienced continued weakening in our Hong Kong market, due, in part, to the
global pandemic and other geopolitical events occurring in the region during the
current year. We continue to work on refining our mainland China cross-border
e-commerce business model and to date have not recognized significant revenues
through this channel. Revenue in Thailand grew steadily during the period, while
Europe remained stable.
Globally, our sales and marketing efforts continue to be directed toward
strengthening our core business through our fiscal year initiatives and building
our worldwide sales. We successfully launched our Protandim® NAD Synergizer,
completed a full on the ground launch of New Zealand, and have plans for future
market expansion. In February 2020, we held our first ever Destination Elite
Academy in Cancun, Mexico which drove distributor excitement. We have plans for
additional events designed to further engage and motivate our distributor base
and provide additional tools and trainings to help them be successful in their
businesses. Throughout the year, we continued the refinement and expansion of
our product offerings internationally and have plans for continued product
expansion in the future. We expect this expansion will continue to drive revenue
growth globally through increased average order size and increased ability to
attract and retain new independent distributors and customers with a compelling
product lineup. We continued investing in our red carpet program, which we
believe has increased our ability to attract and retain strong distributor
leadership and drive revenue growth throughout our markets. We remain committed
to further refining and developing our Greater China market, including our
cross-border e-commerce business model to take advantage of the growth
opportunities in that region.
Gross Margin. Cost of sales were $38.0 million for the fiscal year ended
June 30, 2020, and $38.0 million for the fiscal year ended June 30, 2019,
resulting in a gross margin of $195.0 million, or 83.7%, and $188.0 million, or
83.2%, respectively. The increase in gross margin as a percentage of revenue is
primarily due to benefits of a price update during the second half of fiscal
2020 and decreased inventory obsolescence and handling costs, partially offset
by changes to our geographic and product sales mix related to the revenue growth
and product expansion outside of the United States.
Commissions and Incentives. Commissions and incentives expenses for the fiscal
year ended June 30, 2020 were $111.6 million or 47.9% of revenue compared to
$108.6 million or 48.1% of revenue for the fiscal year ended June 30, 2019. The
increase of $3.0 million in fiscal 2020 was due to the increase in revenue.
Commissions and incentives expenses as a percentage of revenue decreased
slightly during the comparable periods due, in part, to continued refinement of
our various promotional and incentive programs during the year.
Commissions and incentives expenses, as a percentage of revenue, may fluctuate
in future periods based on the timing and magnitude of compensation, incentive
and promotional programs.
Selling, General and Administrative. Selling, general and administrative
expenses for the fiscal year ended June 30, 2020 were $67.9 million or 29.2% of
revenue compared to $69.6 million or 30.8% of revenue for the fiscal year ended
June 30, 2019. The decrease of $1.6 million during the current period primarily
was due to decreased expenses associated with employee
                                       42
--------------------------------------------------------------------------------

compensation costs, including both cash and stock incentive compensation, and
decreased events expenses as a result of changes to our event schedule and due
to the cancellation of events as a result of meeting restrictions related to the
COVID-19 pandemic. The decreases were partially offset by increased depreciation
expenses due to digital assets placed in service and the acceleration of
depreciation on various leasehold assets as well as increased bank fees due to
our increased revenues during the year.
Primary factors that may cause our selling, general and administrative expenses
to fluctuate in the future include changes in the number of employees, the
timing and number of events we hold, marketing and branding initiatives and
costs related to legal matters, if and as they arise. A fluctuation in our stock
price may also impact our share-based compensation expense recorded for equity
awards made in future years.
Other Expense. We recognized other expense for the fiscal year ended June 30,
2020 of $0.8 million as compared to $0.6 million for the fiscal year ended
June 30, 2019. The increase of $0.2 million was due to increased foreign
exchange losses associated with the settlement of foreign transactions and net
losses in currency hedges, both due to an increase in foreign exchange rate
fluctuation during fiscal 2020. These losses were partially offset by a decrease
in interest expense related to our term loan that was repaid in full during the
year.
The following table sets forth interest expense for the fiscal years ended June
30, 2020 and 2019 (in thousands):
                                                                       For 

the fiscal years ended June 30,


                                                                            2020                    2019

Contractual interest expense:



2016 Term Loan                                                      $            44            $       227

Amortization of deferred financing fees:



2016 Term Loan                                                                    7                      6

Amortization of debt discount:



2016 Term Loan                                                                   39                     36
Other                                                                            30                     54
Total interest expense                                              $           120            $       323


Income Tax Expense. Our income tax expense for the fiscal year ended June 30,
2020 was $3.1 million as compared to income tax expense of $1.8 million for the
fiscal year ended June 30, 2019.
The effective tax rate was 21.2% of pre-tax income for the fiscal year ended
June 30, 2020, compared to 19.5% for the fiscal year ended June 30, 2019. The
tax rates for both fiscal 2020 and fiscal 2019 were favorably benefited by
discrete book to tax differences resulting from the vesting of performance
restricted stock units and favorable return to provision adjustments that
occurred during the periods. The effective tax rates for both periods reflect
the federal tax reform legislation enacted during December 2017 that reduced the
federal corporate tax rate to 21%.
Our provision for income taxes for the fiscal year ended June 30, 2020 consisted
primarily of federal, state, and foreign tax on anticipated fiscal 2020 income
which was partially offset by tax benefits. We expect our effective rate to
fluctuate in future periods based on the impact of permanent items in relation
to pre-tax income.
Net Income. As a result of the foregoing factors, net income for the fiscal year
ended June 30, 2020 increased to $11.5 million compared to $7.4 million for the
fiscal year ended June 30, 2019.
Comparison of Fiscal Years Ended June 30, 2019 and 2018
For a discussion of our results of operations for the fiscal 2019 compared with
fiscal 2018, refer to "Part II. Item 7. Management's Discussion and Analysis of
Financial Condition and Results of Operations" in our annual report on Form 10-K
for the fiscal year ended June 30, 2019, as filed with the SEC on August 14,
2019.
Liquidity and Capital Resources
Liquidity
Our primary liquidity and capital resource requirements are to service our debt,
which includes any outstanding balances under the 2016 Credit Facility, and
finance the cost of our planned operating expenses and working capital
(principally inventory purchases), as well as capital expenditures. We have
generally relied on cash flow from operations to fund operating activities and
we have, at times, incurred long-term debt in order to fund stock repurchases
and strategic transactions.
                                       43
--------------------------------------------------------------------------------

At June 30, 2020, our cash and cash equivalents were $22.1 million. This
represented an increase of $3.3 million from the $18.8 million in cash and cash
equivalents as of June 30, 2019.
During the fiscal year ended June 30, 2020, our net cash provided by operating
activities was $18.3 million as compared to net cash provided by operating
activities of $17.8 million during the fiscal year ended June 30, 2019. The
increase in cash provided by operating activities during the fiscal year ended
June 30, 2020 primarily was due to increases in net income and depreciation
expense, partially offset by an increase in cash used for prepaid expenses and
other long-term assets and cash used for operating payables.
During the fiscal year ended June 30, 2020, our net cash used in investing
activities was $2.7 million, as a result of the purchase of fixed assets. During
the fiscal year ended June 30, 2019, our net cash used in investing activities
was $4.5 million, as a result of the purchase of fixed assets and investments in
convertible notes receivable.
Cash used in financing activities during the fiscal year ended June 30, 2020 was
$12.4 million, as a result of our quarterly principal payments on the 2016 Term
Loan, which was repaid in full during fiscal 2020, shares purchased as payment
of tax withholding upon vesting of employee equity awards and the repurchase of
company stock, partially offset by proceeds from stock option exercises and
proceeds from purchases of company stock under our employee stock purchase plan.
Cash used in financing activities during the fiscal year ended June 30, 2019 was
$11.1 million, as a result of principal payments on the 2016 Term Loan,
repurchases of company stock and shares purchased as payment of tax withholding
upon vesting of employee equity awards.
At June 30, 2020 and 2019, the total amount of our foreign subsidiary cash was
$6.8 million and $6.3 million, respectively. The December 2017 tax reform
previously mentioned enacted a 100% dividend deduction for > 10% owned foreign
corporations. Therefore, in the future, if needed, we expect to be able to
repatriate cash from foreign subsidiaries without paying additional U.S. taxes.
At June 30, 2020, we had working capital (current assets minus current
liabilities) of $18.8 million compared to working capital of $17.0 million at
June 30, 2019. The increase in working capital primarily was due to increases in
cash and decreases in accounts payable, partially offset by an increase in
commissions payable. Also, the notes receivable balance was converted to
non-current equity securities. We believe that our cash and cash equivalents
balances and our ongoing cash flow from operations will be sufficient to satisfy
our cash requirements for at least the next 12 months. The majority of our
historical expenses have been variable in nature and as such, a potential
reduction in the level of revenue would reduce our cash flow needs. In the event
that our current cash balances and future cash flow from operations are not
sufficient to meet our obligations or strategic needs, we would consider raising
additional funds, which may not be available on terms that are acceptable to us,
or at all. Our credit facility, however, contains covenants that restrict our
ability to raise additional funds in the debt markets and repurchase our equity
securities without prior approval from the lender. Additionally, our credit
facility provides for a revolving loan facility in an aggregate principal amount
up to $5.0 million. We would also consider realigning our strategic plans
including a reduction in capital spending and expenses.
Capital Resources
Shelf Registration Statement
On March 24, 2020, we filed a shelf registration statement (the "Shelf
Registration") on Form S-3 with the SEC that was declared effective April 3,
2020, which permits us to offer up to $75 million of common stock, preferred
stock, debt securities and warrants in one or more offerings and in any
combination, including in units from time to time. Our Shelf Registration is
intended to provide us with additional flexibility to access capital markets for
general corporate purposes, which may include, among other purposes, working
capital, capital expenditures, other corporate expenses and acquisitions of
assets, licenses, products, technologies or businesses.
2016 Credit Facility
On March 30, 2016, we entered into a loan agreement (the "2016 Loan Agreement")
to refinance our outstanding debt. In connection with the 2016 Loan Agreement
and on the same date, we entered into a security agreement (the "Security
Agreement"). The 2016 Loan Agreement provides for a term loan in an aggregate
principal amount of $10.0 million (the "2016 Term Loan") and a revolving loan
facility in an aggregate principal amount not to exceed $2.0 million (the "2016
Revolving Loan," and collectively with the 2016 Term Loan, the 2016 Loan
Agreement and the Security Agreement, the "2016 Credit Facility").
The principal amount of the 2016 Term Loan is payable in consecutive quarterly
installments in the amount of $0.5 million plus accrued interest beginning with
the fiscal quarter ended June 30, 2016. If we borrow under the 2016 Revolving
Loan, interest will be payable quarterly in arrears on the last day of each
fiscal quarter.
                                       44
--------------------------------------------------------------------------------

On May 4, 2018, we entered into a loan modification agreement, which amended the
2016 Credit Facility ("Amendment No. 1"). Amendment No. 1 revised the maturity
date from March 30, 2019 to March 31, 2021 and increased the fixed interest rate
for the term loan from 4.93% to 5.68%. Amendment No. 1 also revised certain
financial covenants. The minimum fixed charge coverage ratio (as defined in
Amendment No. 1) was revised from a minimum of 1.50 to 1.00 to 1.25 to 1.00,
measured on a trailing twelve-month basis, at the end of each fiscal quarter.
The minimum working capital was increased from $5.0 million to $8.0 million. The
funded debt to EBITDA ratio was replaced with the total liabilities to tangible
net worth ratio (as defined in Amendment No. 1) of not greater
than 3.00 to 1.00 at the end of each quarter. The minimum tangible net worth
measure was removed from the financial covenants.
Loans outstanding under the 2016 Credit Facility, as amended, may be prepaid in
whole or in part at any time without premium or penalty. In addition, if, at any
time, the aggregate principal amount outstanding under the 2016 Revolving Loan,
as amended, exceeds $2.0 million, we must prepay an amount equal to such excess.
Any principal amount of the 2016 Term Loan, as amended, which is prepaid or
repaid may not be re-borrowed.
On February 1, 2019, we entered into a loan modification agreement, which
amended the 2016 Credit Facility, as amended ("Amendment No. 2"). Under
Amendment No. 2, we made a principal payment of $2.0 million and increased the
revolving loan facility from $2.0 million to $5.0 million. Amendment No. 2 also
revised certain financial covenants. The minimum fixed charge coverage ratio (as
defined in Amendment No. 2) was revised from a minimum
of 1.25 to 1.00 to 1.10 to 1.00, measured on a trailing twelve-month basis, at
the end of each fiscal quarter. The minimum working capital was decreased
from $8.0 million to $6.0 million.
The 2016 Credit Facility, as amended, contains customary covenants, including
affirmative and negative covenants that, among other things, restrict our
ability to create certain types of liens, incur additional indebtedness, declare
or pay dividends on or redeem capital stock, make other payments to holders of
our equity interests, make certain investments, purchase or otherwise acquire
all or substantially all the assets or equity interests of other companies, sell
assets or enter into consolidations, mergers or transfers of all or any
substantial part of our assets. As of June 30, 2020, we were in compliance with
all applicable non-financial and restrictive covenants under the 2016 Credit
Facility, as amended.
The 2016 Credit Facility, as amended, also contains various financial covenants
that require us to maintain certain consolidated working capital amounts, total
liabilities to tangible net worth ratios and fixed charge coverage ratios.
Specifically, we must:
•Maintain a minimum fixed charge coverage ratio (as defined in the 2016 Loan
Agreement, as amended) of at least 1.10 to 1.00 at the end of each fiscal
quarter, measured on a trailing twelve month basis;
•Maintain minimum consolidated working capital (as defined in the 2016 Loan
Agreement, as amended) at the end of each fiscal quarter of at least $6.0
million; and
•Maintain a ratio of total liabilities to tangible net worth (as defined in the
2016 Loan Agreement, as amended) of not greater than 3.00 to 1.00 at the end of
each quarter, measured on a trailing twelve month basis.
During the fiscal year ended June 30, 2020, we repaid, in full, the remaining
balance of the 2016 Term Loan in accordance with the terms of the 2016 Credit
Facility, as amended.
Commitments and Obligations
The following table summarizes our contractual payment obligations and
commitments as of June 30, 2020 (in thousands):
                                                             Payments due by period
                                                    Less than
Contractual Obligations                Total         1 year        1-3 years      3-5 years      Thereafter
Operating lease obligations (1)     $ 22,614       $  2,549       $  5,310       $  3,298       $  11,457
Other operating obligations (2)       20,981         13,231          6,272          1,478               -
Total                               $ 43,595       $ 15,780       $ 11,582       $  4,776       $  11,457

(1) Operating lease obligations include current and future obligations associated with

corporate office leases. (2) Other operating obligations represent contractual obligations primarily related to

marketing and sponsorship commitments and purchases of inventory.




Off-Balance Sheet Arrangements
At June 30, 2020 and 2019, we had no off-balance sheet arrangements.
                                       45
--------------------------------------------------------------------------------

Critical Accounting Policies
We prepare our financial statements in conformity with accounting principles
generally accepted in the United States of America. As such, we are required to
make certain estimates, judgments, and assumptions that we believe are
reasonable based upon the information available. These estimates and assumptions
affect the reported amounts of assets and liabilities at the date of the
financial statements and the reported amounts of revenue and expenses during the
periods presented. Actual results could differ from these estimates. Our
significant accounting policies are described in Note 2 to our consolidated
financial statements. Certain of these significant accounting policies require
us to make difficult, subjective, or complex judgments or estimates. We consider
an accounting estimate to be critical if (1) the accounting estimate requires us
to make assumptions about matters that were highly uncertain at the time the
accounting estimate was made and (2) changes in the estimate that are reasonably
likely to occur from period to period, or use of different estimates that we
reasonably could have used in the current period, would have a material impact
on our financial condition or results of operations.
There are other items within our financial statements that require estimation,
but are not deemed critical as defined above. Changes in estimates used in these
and other items could have a material impact on our financial statements.
Management has discussed the development and selection of these critical
accounting estimates with our board of directors, and the audit committee has
reviewed the disclosures noted below.
Allowances for Product Returns
We record allowances for product returns at the time we ship the product based
on estimated return rates. Subject to some exceptions based on local
regulations, our return policy is to provide a full refund for product returned
within 30 days. After 30 days of purchase, only unopened product that is in a
resalable and restockable condition may be returned within twelve months of
purchase and shall receive a 100% refund, less a 10% handling and restocking fee
and any shipping and handling costs. As of June 30, 2020, our shipments of
products sold totaling approximately $21.7 million were subject to our return
policy.
We monitor our product returns estimate on an ongoing basis and revise the
allowances to reflect our experience. Our allowance for product returns was $0.3
million at June 30, 2020, compared with $0.4 million at June 30, 2019. To date,
product expiration dates have not played any role in product returns, and we do
not expect they will in the future as it is unlikely that we will ship product
with an expiration date earlier than the latest allowable product return date.
Inventory Valuation
We value our inventory at the lower of cost or net realizable value on a
first-in, first-out basis. Accordingly, we reduce our inventories for the
diminution of value resulting from product obsolescence, damage or other issues
affecting marketability equal to the difference between the cost of the
inventory and its estimated net realizable value. Factors utilized in the
determination of estimated net realizable value include (i) current sales data
and historical return rates, (ii) estimates of future demand, (iii) competitive
pricing pressures, (iv) new production introductions, (v) product expiration
dates, and (vi) component and packaging obsolescence.
During the fiscal years ended June 30, 2020 and 2019, we recognized expenses of
$0.4 million and $0.8 million, respectively, related to obsolete and slow-moving
inventory.
Revenue Recognition
Revenue is recognized when control of the promised goods or services are
transferred to the customer, in an amount that reflects the consideration we
expect to be entitled to in exchange for those goods or services. Sales, value
add, and other taxes that we collect concurrent with revenue-producing
activities are excluded from revenue.
Stock-Based Compensation
We use the fair value approach to account for stock-based compensation in
accordance with current accounting guidance. We recognize compensation costs for
awards with performance conditions when we conclude it is probable that the
performance conditions will be achieved. We reassess the probability of vesting
at each balance sheet date and adjust compensation costs based on our
probability assessment. For awards with market-based performance conditions, the
cost of the awards is recognized as the requisite service is rendered by the
employees, regardless of when, if ever, the market-based performance conditions
are satisfied.
Research and Development Costs
We expense all of our costs related to research and development activities as
incurred.
Legal Accruals
                                       46

--------------------------------------------------------------------------------



We are occasionally involved in lawsuits and disputes arising in the normal
course of business. Management regularly reviews all pending litigation matters
in which we are involved and establishes accruals as we deem appropriate for
these litigation matters when a probable loss estimate can be made. Estimated
accruals require management judgment about future events. The results of
lawsuits are inherently unpredictable and unfavorable resolutions could occur.
As such, the amount of loss may differ from management estimates.
Recently Issued Accounting Standards
Refer to "Item 8. Financial Statements and Supplementary Data" and Note 2 to our
consolidated financial statements included in Part IV, Item 15 of this report
for discussion regarding the impact of accounting standards that were recently
issued but not yet effective, on our consolidated financial statements.

© Edgar Online, source Glimpses